Synonyms: Compound A [WO2022119905A2]
Compound class:
Synthetic organic
Comment: Uplarafenib is the INN for a BRAF inhibitor that was designed as an antineoplastic agent. It is one of the compounds claimed in patent WO2022119905A2 (NeuPharma) [1]. Uplarafenib is likely Henlius/NeuPharma lead BRAF asset HLX208 (RX208), that is designed to target oncogenic BRAFV600E.
|
|
References |
1. Qian X. (2022)
Certain chemical entities, compositions, and methods. Patent number: WO2022119905A2. Assignee: Neupharma, Inc. Priority date: 01/12/2021. Publication date: 09/06/2022. |